IOZK article on treatment trials for glioblastoma in the specialist journal: "Austin Oncology Case Report"

The IOZK working group published a scientific article in the specialist journal "Austin Oncology Case Report". In this study, patients with glioblastoma were retrospectively examined as part of individual treatment trials - under tumor-specific immunomodulation using modulated electro-hyperthermia in combination with oncolytic virotherapy - in addition to chemotherapy with Temodal. Adjuvant therapy provides indications of a better therapeutic effect if, in addition to chemotherapy, immunological therapy is also carried out to induce immunogenic cell death of the tumor cells. The biomarkers that indicate this were demonstrated here.

The data suggest that the combination of hyperthermia and virotherapy during therapy with Temodal has obvious advantages in terms of improving overall survival. While treatment with chemotherapy is only effective on dividing tumor cells, this additional method induces immunogenic cell death independent of division.

• The Induction of Immunogenic Cell Death (ICD) During Maintenance Chemotherapy and Subsequent Multimodal Immunotherapy for Glioblastoma (GBM). Authors: Van Gool SW, Makalowski J, Feyen O, Prix L, Schirrmacher V and Stuecker W.